Could some heart patients safely stop blood thinners after ablation?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. Inclusion Criteria * Participants must meet all of the following criteria: * Age ≥18 years. * Documented history of atrial fibrillation (paroxysmal or persistent). * Successful catheter ablation for atrial fibrillation performed within the previous 3-6 months. * Maintenance of sinus rhythm after ablation, confirmed by follow-up electrocardiography or rhythm monitoring. * History of percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation. * Completion of the recommended duration of dual antiplatelet therapy (DAPT) following PCI. * Currently receiving oral anticoagulation therapy with a non-vitamin K antagonist oral anticoagulant (NOAC). * Clinically stable and considered eligible for long-term antithrombotic therapy adjustment by the treating physician. * Ability to understand the study procedures and provide written informed consent. 2. Exclusion Criteria * Participants will be excluded if any of the following criteria are present: * Recurrent atrial fibrillation documented after the index ablation procedure requiring repeat ablation or antiarrhythmic escalation. * Presence of mechanical heart valve or moderate-to-severe mitral stenosis. * Indication for long-term anticoagulation independent of atrial fibrillation (e.g., venous thromboembolism, mechanical valve). * Recent acute coronary syndrome or PCI within the past 3 months. * Planned coronary revascularization or cardiac surgery. * History of intracranial hemorrhage or other major bleeding that contraindicates antithrombotic therapy. * Severe renal dysfunction (e.g., estimated glomerular filtration rate \<30 mL/min/1.73 m²). * Severe hepatic dysfunction associated with coagulopathy. * Known hypersensitivity or contraindication to aspirin or NOAC therapy. * Pregnancy or breastfeeding. * Life expectancy less than 1 year due to non-cardiovascular comorbidities. * Participation in another interventional clinical trial that may interfere with the study outcomes.